OrthoPediatrics Q4 2021 Earnings Report
Key Takeaways
OrthoPediatrics Corp. reported a 31% increase in revenue for the fourth quarter of 2021, reaching $24.8 million compared to $18.9 million in the same period last year. The growth was primarily driven by strong performance in trauma and deformity, with international revenue showing a significant increase. The company also issued full year 2022 revenue guidance of $118 million to $121 million and expects positive adjusted EBITDA for the full year 2022.
Helped an estimated 9,500 children in Q4 2021 and a record 38,000 for the full year, bringing the total to over 234,000 since inception.
Total revenue for Q4 2021 was $24.8 million, a 31% increase year-over-year, with domestic revenue up 11% and international revenue up 363%.
Record total annual revenue for 2021 reached $98.0 million, a 38% increase year-over-year, with domestic revenue up 24% and international revenue up 150%.
Adjusted EBITDA loss for full year 2021 improved by $5.7 million compared to 2020.
OrthoPediatrics
OrthoPediatrics
OrthoPediatrics Revenue by Segment
OrthoPediatrics Revenue by Geographic Location
Forward Guidance
OrthoPediatrics expects total 2022 revenue of approximately $118 million to $121 million and to generate several million dollars of positive adjusted EBITDA for the full year 2022.
Positive Outlook
- Company expects total 2022 revenue of approximately $118 million to $121 million dollars, representing growth of 20% to 23% compared to full year 2021.
- The Company also expects to generate several million dollars of positive adjusted EBITDA for the full year 2022.
Challenges Ahead
- The Company remains cognizant of the unique external operating environment due to COVID-19 and its impact on elective procedures.
- COVID-19 may impact healthcare infrastructure and staffing levels.
Revenue & Expenses
Visualization of income flow from segment revenue to net income